Gene study aims to personalize prostate cancer care
NCT ID NCT02705846
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study follows over 4,000 men with prostate cancer, some with rare gene mutations (BRCA1, BRCA2, HOXB13, Lynch Syndrome) and some without. Researchers will track their treatment results and survival over time. The goal is to learn whether these mutations affect how the disease progresses, which could help tailor future treatments.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this study could guide doctors on the best prostate cancer treatments for men with specific gene mutations, potentially improving survival.
- What could go wrong
- This is an observational study, not a treatment trial. It will not directly benefit participants and may take years to yield clear guidance.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Institute of Cancer Research and Royal Marsden Hospital
RECRUITINGSutton, Surrey, SM2 5PT, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new tracer light up hidden prostate cancer?
- Could deep breaths before surgery ward off Post-Op confusion?
- A second look: MRI screening may spot hidden prostate cancers
- Can precision protons spare the bowel in prostate cancer?
- AI coaches doctors on cancer risk talks
- Can an immune booster make hormone therapy work better against prostate cancer?